{"id": "article-29036_0", "title": "Simvastatin -- Continuing Education Activity", "content": "Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet. It is a semi-synthetic derivative of lovastatin, the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke. However, there are several more effective statins with more favorable adverse effect profiles. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, and monitoring, of simvastatin, so providers can direct patient therapy in treating hyperlipidemia as part of the interprofessional team.", "contents": "Simvastatin -- Continuing Education Activity. Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet. It is a semi-synthetic derivative of lovastatin, the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke. However, there are several more effective statins with more favorable adverse effect profiles. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, and monitoring, of simvastatin, so providers can direct patient therapy in treating hyperlipidemia as part of the interprofessional team."}
{"id": "article-29036_1", "title": "Simvastatin -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of simvastatin. Review the indications for using simvastatin in lipid control. Explain the adverse event profile of simvastatin and how it compares with other statin medications. Summarize interprofessional team strategies for improving care coordination and communication to examine simvastatin use and improve patient outcomes. Access free multiple choice questions on this topic.", "contents": "Simvastatin -- Continuing Education Activity. Objectives: Identify the mechanism of action of simvastatin. Review the indications for using simvastatin in lipid control. Explain the adverse event profile of simvastatin and how it compares with other statin medications. Summarize interprofessional team strategies for improving care coordination and communication to examine simvastatin use and improve patient outcomes. Access free multiple choice questions on this topic."}
{"id": "article-29036_2", "title": "Simvastatin -- Indications", "content": "Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet, exercise, weight loss, and possibly other medications as\u00a0part\u00a0of an overall lipid-lowering and cardiovascular\u00a0health regimen. It is a semi-synthetic derivative of lovastatin,\u00a0the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke.", "contents": "Simvastatin -- Indications. Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet, exercise, weight loss, and possibly other medications as\u00a0part\u00a0of an overall lipid-lowering and cardiovascular\u00a0health regimen. It is a semi-synthetic derivative of lovastatin,\u00a0the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke."}
{"id": "article-29036_3", "title": "Simvastatin -- Indications -- FDA-Approved Indications", "content": "Homozygous/heterozygous familial hypercholesterolemia Heterozygous NonFamilial hypercholesterolemia Hypertriglyceridemia Dysbetalipoproteinemia Reduction of adverse cardiovascular events Simvastatin is also used off-label for prophylactic and therapeutic indications.", "contents": "Simvastatin -- Indications -- FDA-Approved Indications. Homozygous/heterozygous familial hypercholesterolemia Heterozygous NonFamilial hypercholesterolemia Hypertriglyceridemia Dysbetalipoproteinemia Reduction of adverse cardiovascular events Simvastatin is also used off-label for prophylactic and therapeutic indications."}
{"id": "article-29036_4", "title": "Simvastatin -- Indications -- Non-FDA-Approved Indications", "content": "Prophylaxis of adverse cardiovascular outcomes post-acute-coronary-syndrome hospitalization Prophylaxis of atrial fibrillation among patients with stable coronary artery disease Simvastatin is\u00a0used as monotherapy and is available in combination products to treat dyslipidemia. Combination products include: Simvastatin/ezetimibe [1] Simvastatin/niacin extended-release (ER)", "contents": "Simvastatin -- Indications -- Non-FDA-Approved Indications. Prophylaxis of adverse cardiovascular outcomes post-acute-coronary-syndrome hospitalization Prophylaxis of atrial fibrillation among patients with stable coronary artery disease Simvastatin is\u00a0used as monotherapy and is available in combination products to treat dyslipidemia. Combination products include: Simvastatin/ezetimibe [1] Simvastatin/niacin extended-release (ER)"}
{"id": "article-29036_5", "title": "Simvastatin -- Mechanism of Action", "content": "Clinicians prescribe statin therapy to lower cholesterol concentrations; simvastatin targets cholesterol production. The biosynthesis of this molecule consists of a multi-step pathway. The rate-limiting step in this pathway involves the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase enzyme. Using acetyl-CoA as a substrate, mevalonic acid is formed, and subsequent reactions lead to the formation of cholesterol. Simvastatin acts on the rate-limiting step and serves as an HMG-CoA reductase inhibitor, consequently leading to decreased cholesterol concentrations.", "contents": "Simvastatin -- Mechanism of Action. Clinicians prescribe statin therapy to lower cholesterol concentrations; simvastatin targets cholesterol production. The biosynthesis of this molecule consists of a multi-step pathway. The rate-limiting step in this pathway involves the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase enzyme. Using acetyl-CoA as a substrate, mevalonic acid is formed, and subsequent reactions lead to the formation of cholesterol. Simvastatin acts on the rate-limiting step and serves as an HMG-CoA reductase inhibitor, consequently leading to decreased cholesterol concentrations."}
{"id": "article-29036_6", "title": "Simvastatin -- Mechanism of Action", "content": "Statins also possess additional properties in addition to their ability to lower cholesterol concentrations. These include inhibition of platelet aggregation, reduction in inflammation at the site of atherosclerotic plaque, and improved endothelial function. These properties are commonly taken advantage of when prescribing statin therapy for\u00a0individuals with normal cholesterol levels. Studies have shown that early statin therapy initiation has\u00a0reduced the incidence of cardiovascular events, leading to reduced mortality. [2]", "contents": "Simvastatin -- Mechanism of Action. Statins also possess additional properties in addition to their ability to lower cholesterol concentrations. These include inhibition of platelet aggregation, reduction in inflammation at the site of atherosclerotic plaque, and improved endothelial function. These properties are commonly taken advantage of when prescribing statin therapy for\u00a0individuals with normal cholesterol levels. Studies have shown that early statin therapy initiation has\u00a0reduced the incidence of cardiovascular events, leading to reduced mortality. [2]"}
{"id": "article-29036_7", "title": "Simvastatin -- Mechanism of Action", "content": "Simvastatin is hepatically metabolized via the CYP450 enzyme system, primarily through CYP3A4 as well as CYP2C6; this figures prominently in some of its potential adverse effects and drug-drug interactions, of which more later. It is a prodrug. It is excreted in the feces and urine and has a half-life of between two and five hours.", "contents": "Simvastatin -- Mechanism of Action. Simvastatin is hepatically metabolized via the CYP450 enzyme system, primarily through CYP3A4 as well as CYP2C6; this figures prominently in some of its potential adverse effects and drug-drug interactions, of which more later. It is a prodrug. It is excreted in the feces and urine and has a half-life of between two and five hours."}
{"id": "article-29036_8", "title": "Simvastatin -- Administration", "content": "Simvastatin is approved for oral administration and is available in 5-mg, 10-mg, 20-mg, 40-mg, and 80-mg tablets. A suspension dosage form is also available for those with difficulty swallowing.", "contents": "Simvastatin -- Administration. Simvastatin is approved for oral administration and is available in 5-mg, 10-mg, 20-mg, 40-mg, and 80-mg tablets. A suspension dosage form is also available for those with difficulty swallowing."}
{"id": "article-29036_9", "title": "Simvastatin -- Administration -- Homozygous Familial Hypercholesterolemia", "content": "40 mg once every evening", "contents": "Simvastatin -- Administration -- Homozygous Familial Hypercholesterolemia. 40 mg once every evening"}
{"id": "article-29036_10", "title": "Simvastatin -- Administration -- Heterozygous Familial Hypercholesterolemia", "content": "Initial 10 to 20 mg once every evening; max dose 40 mg once every evening Pediatric patients age 10 to 17: Initial 10 mg once every evening;\u00a0max dose 40 mg once every evening", "contents": "Simvastatin -- Administration -- Heterozygous Familial Hypercholesterolemia. Initial 10 to 20 mg once every evening; max dose 40 mg once every evening Pediatric patients age 10 to 17: Initial 10 mg once every evening;\u00a0max dose 40 mg once every evening"}
{"id": "article-29036_11", "title": "Simvastatin -- Administration -- Hypertriglyceridemia", "content": "Initial 10 to 20 mg once every evening; max dose 40 mg once every evening", "contents": "Simvastatin -- Administration -- Hypertriglyceridemia. Initial 10 to 20 mg once every evening; max dose 40 mg once every evening"}
{"id": "article-29036_12", "title": "Simvastatin -- Administration -- Reduction in Cardiovascular Events", "content": "Initial 10 to 20 mg once every evening; max dose 40 mg once every evening In patients with coronary heart disease (CHD), the initial dose is 40 mg once every evening", "contents": "Simvastatin -- Administration -- Reduction in Cardiovascular Events. Initial 10 to 20 mg once every evening; max dose 40 mg once every evening In patients with coronary heart disease (CHD), the initial dose is 40 mg once every evening"}
{"id": "article-29036_13", "title": "Simvastatin -- Administration", "content": "A dose restriction exists for simvastatin 80 mg due to a higher risk of myopathy and possible\u00a0rhabdomyolysis, especially within the first 12 months of use. Therefore, the 80-mg strength is restricted\u00a0for only those patients who have been on the 80-mg regimen for 12 or more months with no reported myopathy. Simvastatin 80 mg is not recommended for patients with LDL targets that\u00a0are not at goal, even with simvastatin 40 mg. Recommendations are to use a high-intensity statin instead. For stable patients on the simvastatin 80-mg dose, a change of therapy\u00a0is necessary if initiating an interacting medication. *Doses are adjusted to target goal LDL levels.", "contents": "Simvastatin -- Administration. A dose restriction exists for simvastatin 80 mg due to a higher risk of myopathy and possible\u00a0rhabdomyolysis, especially within the first 12 months of use. Therefore, the 80-mg strength is restricted\u00a0for only those patients who have been on the 80-mg regimen for 12 or more months with no reported myopathy. Simvastatin 80 mg is not recommended for patients with LDL targets that\u00a0are not at goal, even with simvastatin 40 mg. Recommendations are to use a high-intensity statin instead. For stable patients on the simvastatin 80-mg dose, a change of therapy\u00a0is necessary if initiating an interacting medication. *Doses are adjusted to target goal LDL levels."}
{"id": "article-29036_14", "title": "Simvastatin -- Administration -- Dose Adjustments", "content": "Dose adjustments are necessary with simvastatin when taken concomitantly with certain pharmacotherapy. Adjustments in simvastatin strength reduce potential statin-associated toxicities, including fatigue and myopathy. Potent CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors, cyclosporine) Simvastatin is contraindicated: Verapamil, diltiazem, dronedarone Max dose is simvastatin 10 mg Amiodarone, amlodipine, ranolazine Max dose is simvastatin 20 mg", "contents": "Simvastatin -- Administration -- Dose Adjustments. Dose adjustments are necessary with simvastatin when taken concomitantly with certain pharmacotherapy. Adjustments in simvastatin strength reduce potential statin-associated toxicities, including fatigue and myopathy. Potent CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors, cyclosporine) Simvastatin is contraindicated: Verapamil, diltiazem, dronedarone Max dose is simvastatin 10 mg Amiodarone, amlodipine, ranolazine Max dose is simvastatin 20 mg"}
{"id": "article-29036_15", "title": "Simvastatin -- Adverse Effects", "content": "Common adverse effects include headaches, myalgia, abdominal pain, gastritis, constipation, upper respiratory infections, elevated AST or ALT, and impaired serum glucose control. [3]", "contents": "Simvastatin -- Adverse Effects. Common adverse effects include headaches, myalgia, abdominal pain, gastritis, constipation, upper respiratory infections, elevated AST or ALT, and impaired serum glucose control. [3]"}
{"id": "article-29036_16", "title": "Simvastatin -- Adverse Effects", "content": "Rarer, yet more severe, causations\u00a0include cardiovascular effects such as atrial fibrillation,\u00a0hepatic abnormalities, including cholestatic hepatitis, greater than a 3-fold elevation in transaminases, jaundice, and potential liver failure. Adverse musculoskeletal effects include greater than a three-fold increase in creatine phosphokinase (CPK) levels, rhabdomyolysis, and compartment syndrome in the lower legs. [4] [5] [6]", "contents": "Simvastatin -- Adverse Effects. Rarer, yet more severe, causations\u00a0include cardiovascular effects such as atrial fibrillation,\u00a0hepatic abnormalities, including cholestatic hepatitis, greater than a 3-fold elevation in transaminases, jaundice, and potential liver failure. Adverse musculoskeletal effects include greater than a three-fold increase in creatine phosphokinase (CPK) levels, rhabdomyolysis, and compartment syndrome in the lower legs. [4] [5] [6]"}
{"id": "article-29036_17", "title": "Simvastatin -- Adverse Effects", "content": "Additional serious reactions include interstitial lung disease, diabetes mellitus, erythema multiforme, leukopenia, hemolytic anemia, thrombocytopenia, and Stevens-Johnson syndrome, although these adverse events are rare.", "contents": "Simvastatin -- Adverse Effects. Additional serious reactions include interstitial lung disease, diabetes mellitus, erythema multiforme, leukopenia, hemolytic anemia, thrombocytopenia, and Stevens-Johnson syndrome, although these adverse events are rare."}
{"id": "article-29036_18", "title": "Simvastatin -- Adverse Effects", "content": "Drug concentrations, and consequently, incidence and severity of adverse effects, can become\u00a0significantly increased\u00a0when coadministered with CYP3A4 inhibitors. Concomitant medications administered with simvastatin should have an assessment performed for potential drug interactions to minimize the risk of adverse effects. Patients are commonly advised to stop eating grapefruits or drinking grapefruit juice while on statin therapy. However, more recent research has shown this risk can be minimized by spacing the consumption of grapefruit and statin dosing. [7]", "contents": "Simvastatin -- Adverse Effects. Drug concentrations, and consequently, incidence and severity of adverse effects, can become\u00a0significantly increased\u00a0when coadministered with CYP3A4 inhibitors. Concomitant medications administered with simvastatin should have an assessment performed for potential drug interactions to minimize the risk of adverse effects. Patients are commonly advised to stop eating grapefruits or drinking grapefruit juice while on statin therapy. However, more recent research has shown this risk can be minimized by spacing the consumption of grapefruit and statin dosing. [7]"}
{"id": "article-29036_19", "title": "Simvastatin -- Contraindications", "content": "Patients with contraindications to simvastatin pharmacotherapy include those\u00a0with active liver disease, including those who have elevated hepatic enzymes, pregnancy, and women who may become pregnant or who are breastfeeding. Concomitant use with certain medications (see above) is also a contraindication with simvastatin, and drug profiles should\u00a0undergo\u00a0a careful review prior to\u00a0initiation.", "contents": "Simvastatin -- Contraindications. Patients with contraindications to simvastatin pharmacotherapy include those\u00a0with active liver disease, including those who have elevated hepatic enzymes, pregnancy, and women who may become pregnant or who are breastfeeding. Concomitant use with certain medications (see above) is also a contraindication with simvastatin, and drug profiles should\u00a0undergo\u00a0a careful review prior to\u00a0initiation."}
{"id": "article-29036_20", "title": "Simvastatin -- Contraindications", "content": "Pregnancy is a known secondary cause of dyslipidemia, leading to a potential increase in triglyceride and LDL-C concentrations. Statin therapy is contraindicated during pregnancy resulting in limited options for dyslipidemia treatment during pregnancy. Alternative treatment options are necessary\u00a0to treat elevated concentrations during pregnancy to minimize associated complications such as hypertriglyceridemia related to acute pancreatitis. Pregnancy has been delayed or avoided in reported cases to avoid the possible\u00a0complications from untreated dyslipidemia. [8] Females of child-bearing potential are advised to use appropriate contraception during treatment with simvastatin. Recommendations are also to avoid breastfeeding if possible; if unavoidable, clinicians need to weigh potential benefits vs. risk profile, although there is no current data on infant harm or adverse effects on breast milk production. [9]", "contents": "Simvastatin -- Contraindications. Pregnancy is a known secondary cause of dyslipidemia, leading to a potential increase in triglyceride and LDL-C concentrations. Statin therapy is contraindicated during pregnancy resulting in limited options for dyslipidemia treatment during pregnancy. Alternative treatment options are necessary\u00a0to treat elevated concentrations during pregnancy to minimize associated complications such as hypertriglyceridemia related to acute pancreatitis. Pregnancy has been delayed or avoided in reported cases to avoid the possible\u00a0complications from untreated dyslipidemia. [8] Females of child-bearing potential are advised to use appropriate contraception during treatment with simvastatin. Recommendations are also to avoid breastfeeding if possible; if unavoidable, clinicians need to weigh potential benefits vs. risk profile, although there is no current data on infant harm or adverse effects on breast milk production. [9]"}
{"id": "article-29036_21", "title": "Simvastatin -- Contraindications", "content": "Although rare, a serious complication of statin therapy is liver toxicity with elevated levels of transaminases. Due to a\u00a0potential increase in liver enzymes, patients with active liver disease and pre-existing elevated transaminases are excluded from simvastatin therapy. Simvastatin can transiently increase transaminase concentrations within the first few months of treatment. These\u00a0subsequently return\u00a0to baseline. The clinician should monitor liver function and enzymes\u00a0while their patients are on simvastatin pharmacotherapy. [10]", "contents": "Simvastatin -- Contraindications. Although rare, a serious complication of statin therapy is liver toxicity with elevated levels of transaminases. Due to a\u00a0potential increase in liver enzymes, patients with active liver disease and pre-existing elevated transaminases are excluded from simvastatin therapy. Simvastatin can transiently increase transaminase concentrations within the first few months of treatment. These\u00a0subsequently return\u00a0to baseline. The clinician should monitor liver function and enzymes\u00a0while their patients are on simvastatin pharmacotherapy. [10]"}
{"id": "article-29036_22", "title": "Simvastatin -- Contraindications", "content": "Contraindicated drugs for concomitant use with simvastatin include atazanavir, chloramphenicol, erythromycin, gemfibrozil, ritonavir, and azole antifungals. This is not an exhaustive list, and complete medication reconciliation is recommended, as with any drug regimen. [11]", "contents": "Simvastatin -- Contraindications. Contraindicated drugs for concomitant use with simvastatin include atazanavir, chloramphenicol, erythromycin, gemfibrozil, ritonavir, and azole antifungals. This is not an exhaustive list, and complete medication reconciliation is recommended, as with any drug regimen. [11]"}
{"id": "article-29036_23", "title": "Simvastatin -- Monitoring", "content": "Continuous laboratory monitoring is not necessary for patients on simvastatin therapy. To gauge therapeutic effectiveness, a lipid profile\u00a0is evaluated four weeks after initiation and periodically after that leading to potential dose adjustments. Liver function tests are also performed at baseline and subsequently, as clinically necessitated, to evaluate\u00a0liver toxicities. Common symptoms include abdominal pain, yellowing of the skin, loss of appetite, and fatigue.\u00a0Creatine kinase levels are also assessed at baseline and periodically after that, especially in high-risk patients such as those with renal insufficiency. Patients with complex medication profiles (polypharmacy) require close monitoring for musculoskeletal and hepatic complaints due to potential simvastatin toxicities and possible drug-drug interactions. [12]", "contents": "Simvastatin -- Monitoring. Continuous laboratory monitoring is not necessary for patients on simvastatin therapy. To gauge therapeutic effectiveness, a lipid profile\u00a0is evaluated four weeks after initiation and periodically after that leading to potential dose adjustments. Liver function tests are also performed at baseline and subsequently, as clinically necessitated, to evaluate\u00a0liver toxicities. Common symptoms include abdominal pain, yellowing of the skin, loss of appetite, and fatigue.\u00a0Creatine kinase levels are also assessed at baseline and periodically after that, especially in high-risk patients such as those with renal insufficiency. Patients with complex medication profiles (polypharmacy) require close monitoring for musculoskeletal and hepatic complaints due to potential simvastatin toxicities and possible drug-drug interactions. [12]"}
{"id": "article-29036_24", "title": "Simvastatin -- Toxicity", "content": "Severe cases of musculoskeletal symptoms warrant discontinuation of simvastatin. In milder cases, the currently accepted practice is temporary discontinuation followed by a re-challenge at a lower dose. If re-challenging simvastatin at a lower dose leads to similar adverse effects, discontinuation followed by an alternative statin is the recommended next step. [13] Discontinuation\u00a0is also warranted if severe hepatotoxicity or hyperbilirubinemia or if jaundice occurs.", "contents": "Simvastatin -- Toxicity. Severe cases of musculoskeletal symptoms warrant discontinuation of simvastatin. In milder cases, the currently accepted practice is temporary discontinuation followed by a re-challenge at a lower dose. If re-challenging simvastatin at a lower dose leads to similar adverse effects, discontinuation followed by an alternative statin is the recommended next step. [13] Discontinuation\u00a0is also warranted if severe hepatotoxicity or hyperbilirubinemia or if jaundice occurs."}
{"id": "article-29036_25", "title": "Simvastatin -- Enhancing Healthcare Team Outcomes", "content": "Simvastatin has\u00a0been used for many years to treat dyslipidemia and high-risk patients such as people with diabetes. Common clinical pearls can help limit potential adverse effects and enhance patient outcomes. Due to an increased risk of myopathy, the 80-mg dose\u00a0is restricted to patients who have been stable on 80 mg for at least 12 months. If additional LDL-lowering\u00a0is required, switch to a high-intensity statin. Use a lower starting dose and monitor for patients who\u00a0are of Chinese descent. [14] Use further caution in patients who are chronic alcohol consumers and/or have a history of liver disease. Avoid the consumption of grapefruit juice, or space the consumption of grapefruit and grapefruit juice from statin dosing. [7]", "contents": "Simvastatin -- Enhancing Healthcare Team Outcomes. Simvastatin has\u00a0been used for many years to treat dyslipidemia and high-risk patients such as people with diabetes. Common clinical pearls can help limit potential adverse effects and enhance patient outcomes. Due to an increased risk of myopathy, the 80-mg dose\u00a0is restricted to patients who have been stable on 80 mg for at least 12 months. If additional LDL-lowering\u00a0is required, switch to a high-intensity statin. Use a lower starting dose and monitor for patients who\u00a0are of Chinese descent. [14] Use further caution in patients who are chronic alcohol consumers and/or have a history of liver disease. Avoid the consumption of grapefruit juice, or space the consumption of grapefruit and grapefruit juice from statin dosing. [7]"}
{"id": "article-29036_26", "title": "Simvastatin -- Enhancing Healthcare Team Outcomes", "content": "Simvastatin therapy can address dyslipidemia in those patients with such a profile. However, newer statin agents with fewer interactions and adverse effects have replaced\u00a0simvastatin as the first-line agent for statin therapy. Currently, it is more common to initiate treatment on these newer agents, leaving simvastatin for those who have had successful results using the drug with no adverse events. For those patients who receive dyslipidemia therapy with simvastatin, the interprofessional healthcare team, consisting of clinicians (MDs, DOs, NPS, and PAs), specialists, nurses, and pharmacists, should work together to monitor for therapeutic results and adverse effects and the pharmacist can suggest equivalent dosing with other statins less prone to adverse events.", "contents": "Simvastatin -- Enhancing Healthcare Team Outcomes. Simvastatin therapy can address dyslipidemia in those patients with such a profile. However, newer statin agents with fewer interactions and adverse effects have replaced\u00a0simvastatin as the first-line agent for statin therapy. Currently, it is more common to initiate treatment on these newer agents, leaving simvastatin for those who have had successful results using the drug with no adverse events. For those patients who receive dyslipidemia therapy with simvastatin, the interprofessional healthcare team, consisting of clinicians (MDs, DOs, NPS, and PAs), specialists, nurses, and pharmacists, should work together to monitor for therapeutic results and adverse effects and the pharmacist can suggest equivalent dosing with other statins less prone to adverse events."}
{"id": "article-29036_27", "title": "Simvastatin -- Enhancing Healthcare Team Outcomes", "content": "When the clinician prescribes simvastatin, the nursing staff should review dosing and administration with the patient and answer patient questions about their medication therapy. It is incumbent on the pharmacist to perform medication reconciliation and verify that there are no potential drug-drug interactions that need to be addressed and that the dosing of the drug is appropriate. Any concerns should be reported to the prescriber or nursing staff, so appropriate measures can be taken to alter the patient's therapy. [15] All interprofessional team members should be vigilant for adverse events and immediately report them to the rest of the team. This interprofessional approach can drive better patient outcomes with fewer side effects. [Level 5]", "contents": "Simvastatin -- Enhancing Healthcare Team Outcomes. When the clinician prescribes simvastatin, the nursing staff should review dosing and administration with the patient and answer patient questions about their medication therapy. It is incumbent on the pharmacist to perform medication reconciliation and verify that there are no potential drug-drug interactions that need to be addressed and that the dosing of the drug is appropriate. Any concerns should be reported to the prescriber or nursing staff, so appropriate measures can be taken to alter the patient's therapy. [15] All interprofessional team members should be vigilant for adverse events and immediately report them to the rest of the team. This interprofessional approach can drive better patient outcomes with fewer side effects. [Level 5]"}
{"id": "article-29036_28", "title": "Simvastatin -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Simvastatin -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}